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Vaccinia virus protein A33 (A33VACV) plays an important role in protection against orthopoxviruses, and hence is
included in experimental multi-subunit smallpox vaccines. In this study we show that single-dose vaccination with
recombinant Sindbis virus expressing A33VACV, is sufficient to protect mice against lethal challenge with vaccinia
virus WR (VACV-WR) and ectromelia virus (ECTV) but not against cowpox virus (CPXV), a closely related orthopoxvirus.
Moreover, a subunit vaccine based on the cowpox virus A33 ortholog (A33CPXV) failed to protect against cowpox and
only partially protected mice against VACV-WR challenge. We mapped regions of sequence variation between A33VACV
and A33CPXVand analyzed the role of such variations in protection. We identified a single protective region located
between residues 104–120 that harbors a putative H-2Kd T cell epitope as well as a B cell epitope - a target for the
neutralizing antibody MAb-1G10 that blocks spreading of extracellular virions. Both epitopes in A33CPXV are mutated
and predicted to be non-functional. Whereas vaccination with A33VACV did not induce in-vivo CTL activity to the
predicted epitope, inhibition of virus spread in-vitro, and protection from lethal VACV challenge pointed to the B cell
epitope highlighting the critical role of residue L118 and of adjacent compensatory residues in protection. This
epitope’s critical role in protection, as well as its modifications within the orthopoxvirus genus should be taken in
context with the failure of A33 to protect against CPXV as demonstrated here. These findings should be considered
when developing new subunit vaccines and monoclonal antibody based therapeutics against orthopoxviruses,
especially variola virus, the etiologic agent of smallpox.
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Variola virus, the causative agent of smallpox, was eradi-
cated following a world-wide vaccination campaign,
launched by the WHO [1]. Highly conserved antigens
(>97% sequence similarity) within the orthopoxvirus
genus, allowed to achieve cross protection against vari-
ola virus by immunization with vaccinia virus (VACV)
vaccine strains. In animal studies, vaccination with
VACV protects mice against virulent mouse-adapted* Correspondence: nirp@iibr.gov.il
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reproduction in any medium, provided the orVACV (WR), ectromelia (ECTV) and cowpox (CPXV)
viruses, rabbits from rabbitpox virus (RPXV) and mon-
keys from monkeypox virus (MPXV) [2].
Although VACV is an efficient vaccine, rare but severe
side effects are associated with the vaccine. Along with
the success of the eradication campaign, vaccination that
was no longer required ceased. As smallpox remains a
potential hazard, highly attenuated vaccine strains – e.g.
MVA and LC16m8 are being extensively evaluated for
potency. In addition, the approach of using protective
VACV antigens is pursued by several labs, aiming at gen-
erating an efficacious and safe subunit vaccine. In this
regard, A33 antigen is one of the most studied and
promising candidates [3-13].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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forming a disulfide-bonded homodimer modified with
N- and O- linked glycosylations and acylation and found
on the surface of extracellular virions (EV) and infected
cells [14-17]. This protein was shown to form a complex
with the viral proteins A36, A34 and B5, thus stabilizing
their presentation on EVs [16,18,19]. A33 is crucial for
virus egress and cell-to-cell spread, and deletion of its
gene, namely A33R, results in a small plaque phenotype
and virus attenuation in-vivo [20-22]. Antibodies against
A33 inhibit virus spread in cell culture as assayed by in-
hibition of comet formation [22,23].
Using A33-based protein or DNA vaccines, several
studies demonstrated the contribution of A33 to protec-
tion against VACV, ECTV and MXPV [3-13]. Moreover,
antibodies to A33 have a major contribution to protec-
tion against VACV challenge [23,24].
In this work we used a recombinant Sindbis virus vec-
tor, based on the Toto 1101 attenuated strain that effi-
ciently infect and replicate in mice without associated
morbidity or mortality. This replicating virus expresses
recombinant proteins cloned downstream to a potent
2nd sub-genomic promoter and therefore induces a ro-
bust immune response in mice [25]. In this work, we
evaluated the efficacy of a Sindbis virus vector express-
ing the vaccinia virus protein A33 (A33VACV) in protec-
tion against several orthopoxviruses. Using this system
we show that A33 vaccination protected mice against
VACV-WR and ECTV but failed to protect against
CPXV challenge. By introducing A33CPXV domains and
residues into A33VACV, we show that protection with
A33VACV based vaccination depends on a single protect-
ive epitope in A33VACV, previously demonstrated in-vitro
to serve as a target for the neutralizing antibody MAb-
1G10 [26,27]. We further map the role of protectiveFigure 1 BALB/c mice tolerate Sindbis pTE vaccination and remain se
intraperitonealy with 5E + 8 or 1E + 9 pfu of Sindbis pTE or left unvaccinate
initial weight profile over 10 days post vaccination is shown (A). 14 days po
1E + 9 pfu of Sindbis virus pTE or unvaccinated) were challenged by intran
any signs of illness. Percent of initial weight profile over 7 days post challen
of the mean (SEM).residues and elaborate on the mechanism of cross-
protection against orthopoxviruses.
Results
Applicability of Sindbis virus as a vaccine vector
In order to evaluate the protective capacity of A33VACV,
we tested the feasibility of using an expression vector
based on a replication competent, recombinant Sindbis
virus (pTE3) [25]. First, we assessed the effect of vaccin-
ating mice with this replicating vector and then we
tested their susceptibility to subsequent VACV infection.
To achieve these goals we vaccinated mice by intraperi-
toneal (i.p.) injection with two doses (5E + 8 and 1E + 9
pfu) of the parental Sindbis virus (Figure 1A). Vaccin-
ation did not cause visible signs of illness with vacci-
nated mice gaining weight similarly or slightly faster
than unvaccinated mice (differences in AUC are not sig-
nificant p > 0.05) (Figure 1A). No additional visible signs
of illness were observed, suggesting low toxicity or
reactogenicity of the vector in vaccinated mice. Next, we
determined the effect of vaccination with the parental
Sindbis virus on the susceptibility of the vaccinated mice
to subsequent intranasal (i.n.) lethal challenge with
VACV-WR of either 15 or 150 LD50. All animals lost
weight and succumbed to infection regardless of previous
vaccination with Sindbis virus (Figure 1B). These results
confirmed the applicability of this virus-based vector for
the evaluation of the protective efficacy of A33VACV.
To confirm the ability of the Sindbis A33VACV vector
to express A33 in infected cells, BHK-21 cells were
infected with the recombinant virus and A33 expression
was determined 24 hours later by immunofluoresence
microscopy. Positive staining for A33 was obtained in
Sindbis-A33 infected cells (Figure 2A) as well as in the
control VACV infected cells (Figure 2C) but not in cellsnsitive to subsequent VACV challenge. BALB/c mice were injected
d (as indicated) and monitored daily for any signs of illness. Percent of
st vaccination the mice (either previously vaccinated with 5E + 8 or
asal instillation with VACV-WR (15 or 150 i.n. LD50) and monitored for
ge is shown (B) (n = 5 per group). Error bars represent standard errors
Figure 2 Expression of A33 in BHK21 cells following infection with Sindbis A33VACV. BHK21 monolayers seeded on glass cover slides were
infected at 0.1 MOI with either Sindbis A33VACV (A), Sindbis pTE (B), VACV-Lister virus (C) or left uninfected (D). 24 hours later the cells were fixed,
permeabilized and stained with rabbit anti A33 and mouse anti Sindbis virus antibodies, followed by staining with goat anti rabbit antibody conjugated
to a 488 nm fluorophore and goat anti mouse antibody conjugated to a 555 nm fluorophore, respectively. Cellular DNA was stained with DAPI.
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(Figure 2B) or in uninfected cells (Figure 2D), where
only faint non-specific staining was observed. Staining
for Sindbis virus in cells infected with Sindbis confirmed
the infection efficiency in both samples (Figure 2A and B).
Sindbis A33 protects against VACV-WR and ECTV
challenge
To evaluate the protective efficacy of Sindbis A33VACV,
BALB/c mice were vaccinated by single i.p. injection
with 107pfu of Sindbis A33VACV or Sindbis pTE as a
negative control. Fifteen days post vaccination animals
were challenged with orthopoxviruses.
When VACV-WR, the commonly used mouse adapted
strain was used to challenge the mice by intranasal (i.n.)
instillation (lethal dose of 4X106pfu corresponding to
200LD50), all A33
VACV vaccinated mice survived while
control Sindbis pTE vaccinated mice and unvaccinated
animals succumbed to infection (Figure 3A). Although
Sindbis A33VACV vaccination prevented mortality, it did
not prevent morbidity (Figure 3B). A33VACV vaccinated
mice lost weight similarly to pTE control vaccinatedmice. Yet, at day 8 post challenge, A33VACV vaccinated
mice began to recover while all control animals died
(Figure 3B).
Intravenous infection with VACV-WR leads to a dis-
ease visually manifested by pock formation on the tails
of the infected mice that can be prevented by vaccin-
ation with VACV, as we have shown previously [28]. We
used this model to evaluate the protective efficacy of
Sindbis A33VACV. We vaccinated CD-1 mice with 107pfu
Sindbis A33VACV and 14 days later we challenged these
animals with 104pfu VACV-WR by i.v. injection. Con-
trol pTE and unvaccinated animals exhibited multiple
pocks on their tails (Figure 3C). In contrast, Sindbis
A33VACVvaccination significantly reduced pock formation
by 70% (P < 0.001). Intradermal scarification with the
conventional smallpox vaccine VACV-Lister completely
prevented pock formation. Thus, our data demonstrate
that single vaccination with Sindbis A33VACV prevents
death and reduces the number of dermal pocks caused by
VACV-WR infection.
We then challenged the Sindbis virus based vaccine
with ECTV – the causative agent of mousepox which is
Figure 3 (See legend on next page.)
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Figure 3 Protection against orthopoxvirus exposure by Sindbis A33VACV. BALB/c mice were vaccinated intraperitonealy with 1E + 7 pfu of
the indicated viruses: Sindbis A33VACV, Sindbis pTE or left unvaccinated. Where indicated (Figure 3C), mice were vaccinated by tail scarification
with 1X106 VACV-Lister. Two weeks later, the mice were challenged with VACV-WR (4E + 6 pfu i.n. corresponding to 200LD50) and monitored for
mortality (A) and weight loss as a measure of morbidity (B). Pocks on the tails were induced in vaccinated or unvaccinated CD-1 mice 14 days
post vaccination by intravenous injection with 1E + 04 pfu of VACV-WR (C). Pocks on the tails were stained with Trypan blue and counted.
Vaccinated mice were challenged with ECTV (10 pfu i.n. corresponding to 10LD50) (D, E) or ECTV by i.f.p. injection (30 pfu corresponding to 3
LD50) (F, G). Mice were weighed daily to monitor morbidity and checked for mortality (n = 6 per group for Figures 3 A & B, n = 5 per group for
Figure 5C and n = 7 per group for Figures 3D, E, F & G). Error bars represent standard errors of the mean (SEM).
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smallpox [29,30]. BALB/c mice are highly susceptible to
ECTV infection either by i.n. instillation or by intra-
footpad (i.f.p) injection. We determined the LD50 values
for BALB/c as: i.n. LD50 = 1pfu and i.f.p LD50 = 10pfu
([29] and our unpublished data).
We vaccinated BALB/c mice with Sindbis A33VACV
and 14 days later challenged them with 10 i.n-LD50 or 3
i.f.p-LD50 ECTV (Figure 3D, E and Figure 3F, G, respect-
ively). Following i.n. challenge, control unvaccinated
mice or pTE vaccinated animals started to lose weight
after 6 days, gradually deteriorated and succumbed to
infection within two weeks (mean time to death
(MTTD) of 10.5 and 8.7, respectively). In contrast, vac-
cination with Sindbis A33VACVprevented mortality and
significantly reduced the extent of weight loss (p < 0.01
comparing the area under the curve of A33 vaccinated
vs pTE or unvaccinated mice, Figure 3D).
A33VACV also protected against 3 i.f.pLD50 challenge
conferring 80% protection from lethality and reducing
the extent of weight loss (Figure 3F, G). In contrast, con-
trol Sindbis pTE vaccinated mice or unvaccinated mice
deteriorated faster and did not survive the challenge.
CPXV escapes A33VACV induced immunity
CPXV is a rodent orthopoxvirus found in nature in the
northern parts of Europe and Asia and occasionally
causes emerging zoonosis [2,31,32]. This virus causes a
lethal disease in lab mice that can be prevented by
smallpox vaccination [28].
To measure the potency of A33VACV based vaccine
against CPXV infection we vaccinated BALB/c mice with
Sindbis A33VACV and 14 days later challenged them with
a lethal dose of CPXV (3 i.n. LD50). In contrast to the effi-
cient protection against VACV-WR and ECTV, A33VACV
vaccinated mice were not protected from a lethal chal-
lenge with CPXV (Figure 4A, B). All mice lost weight and
died at a similar rate regardless of vaccination. To check
whether the basis for the failure of A33VACV to protect
against CPXV is sequence variation in A33, we generated
a recombinant Sindbis virus encoding the CPXV ortholog
of A33 (A33CPXV). Similar to vaccination with A33VACV,
vaccination with A33CPXV neither protected nor pre-
vented morbidity against 3 i.n. LD50 challenge of CPXV(Figure 4C, D), excluding the possibility that sequence
variation prevents A33VACV from protecting against CPXV
challenge. When we tested the ability of A33CPXV to pro-
tect against VACV-WR challenge (20 i.n. LD50), A33
CPXV
vaccinated mice were morbid and 40% succumbed to in-
fection whereas all A33VACV survived and were less mor-
bid (Figure 4E, F). All control Sindbis pTE vaccinated and
unvaccinated mice succumbed to the infection. Thus, the
data indicate that CPXV evades the protective immune
response induced by A33VACV or by A33CPXV. We further
show that unlike A33VACV, A33CPXVonly partially protects
against VACV-WR challenge, suggesting that protective
epitope(s) in A33VACV that confer protection against
VACV and ECTV are modified in A33CPXV making
A33CPXV less protective.
Mapping the protective region in A33
To elucidate the mechanism underlying the inability of
A33 to protect against CPXV, we looked for differences
in A33 between A33VACV and A33CPXV. Additional se-
quences of monkeypox Zair (MPXV-ZAR), ectromelia
virus Moscow (ECTV-Moscow) and Variola major virus
starin Bangladesh (VARV-BGD74_sol) were included to
elaborate on the role of these sequence variations in
pathology of virulent orthopox and protection capacity
of molecular vaccines. Comparison of the amino acid
(aa) sequences of VACV and CPXV revealed two main
regions harboring differences between VACV and CPXV
encompassing aa S82-S89 and L112-L118 which we
termed CP-I and CP-II, respectively (Figure 5A). The aa
changes in CP-I region are unique to CPXV while
changes in CP-II appear also in the listed species. The aa
sequence of A33 is identical for VACV-WR (the chal-
lenge strain) and for VACV-Lister (the vaccine strain).
In order to elaborate on the role of these two regions in
protection, two chimeric molecules were constructed by
replacing the A33VACV CP-I and CP-II regions with the
corresponding CPXV sequences. The chimeric A33
genes were introduced to the Sindbis expression system.
Mice were vaccinated with the recombinant Sindbis
virus encoding A33VACV, A33CPXV or the chimeric A33
proteins, and 14 days post vaccination were challenged
by intranasal instillation with either VACV-WR (20LD50)
or CPXV (3LD50). Replacement of the A33
VACV backbone
Figure 4 A33 vaccination does not protect against Cowpox virus. Mice were vaccinated with 1E + 7 pfu of the indicated viruses: Sindbis
A33VACV, Sindbis pTE or left unvaccinated. Two weeks later, the mice were challenged with CPXV Brighton-red (3E + 5 pfu corresponding to 3 i.n.
LD50) and monitored for morbidity (A) and mortality (B). (n = 5). In a different experiment mice were similarly vaccinated with an additional group
vaccinated with Sindbis A33CPXV. Two weeks later, the mice were challenged with CPXV Brighton-red (3E + 5 pfu corresponding to 3 i.n. LD50) (C, D) or
VACV-WR (4E + 5 corresponding to 20 i.n. LD50) (E, F). Uninfected mice served as a control. Error bars represent standard errors of the mean (SEM).
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ive capacity of A33VACV and the mice recovered similarly
to A33VACV vaccination (Figure 5B). However, replace-
ment of the A33VACV backbone with A33 CP-II region
resulted in loss of protection against VACV-WR challenge
(Figure 5B). None of the tested constructs provided pro-
tection against CPXV challenge (Figure 5C). The loss of
protection that resulted from replacement of the CP-II re-
gion of VACV with the corresponding CPXV region, sug-
gests that CP-II harbors protective epitope(s). This epitope
is not protective in the corresponding CP-II region of
CPXV.Identification of the critical residues for protection in A33
Next, we wanted to identify which of the residues in CP-
II contribute to protection. The CP-II region in A33CPXV
harbors the following amino acid substitutions compared
to A33VACV: L112F, Q117K and L118S (Figure 6A). The
L112F substitution is shared also by variola virus
(VARV-BGD74_sol) while the Q117K and L118S substi-
tutions are found in monkeypox (MPXV-ZAR) and
ectromelia (ECTV-Moscow) but not in VARV. Both
MPXV and ECTV share also the S120E substitution. To
check which of these substitutions abrogates protection,
we generated modified A33VACV genes harboring the
Figure 5 Mapping the protective epitope to the CP II region in A33. Alignment of the amino-acid sequence (aa 73–137) of A33VACVof: VACV-
WR (Vaccinia virus – Western Reserve) with the ortholog A33 of CPXV-BR (CPXV Brighton red), MPXV-Zar (monkeypox Zaire), ECTV-Moscow and
VARV-BGD74-sol (Bangladesh 74). CP I and CP II represent two regions with variable changes between the sequences (A). BALB/c mice were
vaccinated with 1E + 7 pfu Sindbis viruses expressing A33VACV, A33CPXV or with A33VACV in which the CP I or CP II regions from A33CPXV were
introduced into its genome replacing the original regions (domain swapping). Two weeks later, the mice were challenged with either VACV-WR
(4E + 5 pfu corresponding to 20 i.n. LD50) (B) or with CPXV Brighton-red (3E + 5 pfu corresponding to 3 i.n. LD50) (C) (n = 5 per group). Error bars
represent standard errors of the mean (SEM).
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of A33VACV . In addition, we also generated a double mu-
tant A33 gene (Q117K-L118S). These modified A33VACV
genes were cloned into the Sindbis expression system.
Recombinant Sindbis viruses were produced and expres-
sion of the modified A33 genes was confirmed by infec-
tion of BHK 21 cells followed by Western blot analysis of
the cell lysates (Figure 6B). A33 is post-translationally
modified in cells (N’ and O’ glycosylations and acylation)
resulting in a well-known multiple band pattern in SDS-
PAGE [14,16,19]. All Sindbis viruses expressed the modi-
fied A33VACV genes, yet certain differences in the multiple
band pattern could be observed, mainly in the double
mutant A33 (Q117K-L118S). Expression of the E1 and
E2 sindbis virus proteins and β-Tubulin confirm the
specificity of A33 detection and serve as infection and
loading controls.
Next, we evaluated the effect of the aa substitutions
on the capacity of A33 to induce immune response and
protection. To analyze the effect of the aa substitutions
on ability of A33 to mount cytotoxic CD8+ T cell
lymphocyte (CTL) dependent cytotoxicity, we performed
in-silico analysis of A33 potential CTL epitopes utilizing 3
independent experimentally based algorithms: NetMHC,
SYFPEITHI and BIMAS [33-35]. Since evaluation of theprotective ability of A33 is performed in BALB/c mice,
the analysis was set to predict epitopes that can bind
the BALB/c MHC class I molecule (H-2Kd and H-2Dd
alleles). All three algorithms identified a single H-2kd
prevalent 9-mer potential CTL epitope in the entire
A33VACVgene spanning aa Y104 to L112, in which the
essential anchoring residue L112 is located at the CP-II
region. In addition, all three algorithms predicted that
the 9–mer peptide harboring the L112F substitution,
representing the CPXV orthologous peptide, would
lose the ability to bind the MHC molecule, a pre-
requisite to elicit CD8+ T-cell cytotoxicity.
To check whether the 9-mer epitope in CPII harboring
L112 is a functional CTL epitope, and whether the
L112F substitution abrogates it, BALB/c mice were vac-
cinated with sindbis A33VACV and 14 days later were
tested for their ability to mount in-vivo CTL activity
(Table 1). Vaccination with VACV-Lister, the licensed
smallpox vaccine and the H-2Kd immune dominant T-cell
epitope of VACV A52 [36] were used as positive controls.
Naïve mice and the unrelated influenza virus H-2Kd CTL
epitope (Influenza A/H3N2/Texas/1/77 NP 147–158) [37]
were used to calculate specific lysis. In support of previous
reports [36], VACV-Lister vaccinated mice mounted about
40% specific lysis of A52 labeled cells unlike naïve,
Figure 6 Expression and induction of antibodies with comet inhibition activity by Sindbis A33 harboring point mutations within the
CP II region. Multiple sequence alignment of A33 CP II region showing amino acid changes between several Orthopoxviruses-VACV-WR
(Vaccinia virus – Western Reserve), CPXV-BR (CPXV Brighton red), MPXV-Zar (monkeypox Zaire), ECTV-Moscow and VARV-BGD74-sol
(Bangladesh 74) (A). Expression analysis of the various A33 genes in lysates of Sindbis A33 infected BHK21 cells separated by SDS-PAGE and
immunoblotted as indicated. MW – Molecular weight (Kda). Arrowheads indicate bands of the different proteins (B). Geometric mean titer
(GMT) (ELISA) in sera of vaccinated mice 21 days post vaccination. Bars represent GeoStDev (C). Comet inhibition activity in sera of Sindbis
A33 vaccinated mice (D, same sera as in C). Serum dilutions are indicated to the left and the type of Sindbis A33 used for vaccination is
indicated at the top.
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tope spanning aa Y104 to L112 of A33VACV did not mount
significant specific lysis neither following sindbis A33VACV
vaccination nor following VACV-Lister vaccination. Inter-
estingly, peptide harboring L112F substitution, predicted
to prevent CTL activity, mounted a weak, yet significant
response. In summary, our results do not support the
presence of a functional H-2Kd CTL epitope spanningTable 1 In vivo CTL activity to A33 peptides in vaccinated
mice




VACV Lister 2.5 (2.9)
Sindbis A33VACV A33CPXV (104–112) 6.1 (2.8)
VACV Lister A52VACV (75–83) 40.4 (6.3)
In vivo CTL activity to the indicated peptides (middle column) was measured
14 days following vaccination of BALB/c mice with the indicated viruses (left
column). Specific lysis (% and StDev) is depicted in the right column.aaY104 to L112. Therefore, the data does not support
the hypothesis that immune evasion of A33 by CPXV is
due to the loss of a CTL epitope through the L112F
substitution.
We then tested the level of serum IgG antibodies
against A33 following vaccination with the various A33
derivatives. All A33 derivatives induced specific anti-
bodies as determined by ELISA using A33VACV as the
capture antigen (Figure 6C). Yet, lower antibody titers
were detected following vaccination with A33CPXV or
the L118S substitution (P = 0.02 and P < 0.01 compared
to A33VACV/A33VACV L112F, respectively). As protective
antibodies against A33 were previously demonstrated to
inhibit EV spread in culture, we analyzed the capacity of
the different sera to inhibit EV spread assayed by comet
formation inhibition. A33VACV as well as the L112F or
Q117K mutants inhibited comet formation. In contrast,
sera from A33CPXV or L118S vaccinated mice poorly
inhibited comet formation (Figure 6D). Comet inhibition
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vaccinated mice inhibited EV spread only partially.
To elucidate the protective capacity of these variations,
vaccinated mice were challenged by intranasal instilla-
tion with VACV-WR (20 LD50, Figure 7). Whereas
L112F and Q117K substitutions protected mice similarly
to A33VACV (100% survival), L118S substitution resulted
in complete loss of protection (Figure 7A). The Q117K -
L118S double substitution resulted in partial protection
(40% survival), and the recovery rate of the surviving an-
imals in this group was slower in comparison to
A33VACV vaccinated mice (p < 0.004) (Figure 7B). Thus,
our data indicates that of the several amino acid differ-
ences between the A33VACV and A33CPXV, L118 as part
of a major protective epitope, significantly contributes to
the protection afforded by active vaccination with A33,
most likely through induction of protective humoral
immunity.
Discussion
In the present study we evaluated the applicability of a
Sindbis-virus based vector for the evaluation of the pro-
tective efficacy of A33VACV. Previous reports demon-
strated the protective capacity of A33 against different
orthopoxviruses such as VACV-WR, ECTV and MPXV
[3-8,13]. We show that a single-dose vaccination of
Sindbis A33VACV efficiently protected mice against viru-
lent VACV-WR and ECTV challenge, but failed to pro-
tect against CPXV challenge. Furthermore, homologous
vaccination with A33CPXV failed to protect against CPXV
and only partially protected against VACV-WR. We
identified a single protective region in A33VACV located
between residues 104–120 that harbors a putative H-
2Kd CD8+ T cell epitope and a B cell epitope. This B
cell epitope was shown to be a target for the neutralizing
antibody MAb-1G10 that blocks spreading of extracellu-
lar virions [26,27]. Both epitopes are affected in A33CPXVFigure 7 Mapping the protective epitope in A33. Mortality (A) and mo
were vaccinated with 1E + 7 pfu of Sindbis viruses expressing the various A
the mice were challenged by i.n. instillation with VACV-WR (4E + 5 pfu corr
errors of the mean (SEM).by 3 amino acids (aa) substitutions L112F, Q117K and
L118S and shown to be non-functional. Vaccination with
a A33VACV, modified to contain each of these substitu-
tions, revealed the critical role of L118 in protection
against VACV-WR and in blocking of EV spread by anti-
bodies. These results support previous studies which
mapped the critical role of L118 in binding the mono-
clonal neutralizing antibody MAb-1G10 and the conse-
quence of each of these substitutions on binding of this
antibody [26,27]. Since A33 is considered an important
contributor to future smallpox subunit vaccines which
might also be used against other orthopoxvirus infections
such as MPXV, and antibodies to A33 are developed for
treatment of orthopoxvirus infections, unraveling the basis
for this protective ability at the single aa level is of major
importance.
In-silico analysis of A33 identified a potential CTL epi-
tope in which L112 is a pivotal anchoring residue. L112F
substitution representing the CPXV orthologous peptide,
abolished the predicted binding to the H-2Kd molecule
thus impairing the ability of A33 to elicit a cellular im-
mune response. The very same substitution is also found
in the VARV homologue A33VARV (Figure 6A) making
this specific residue of interest. In contrast to the in-
silico predictions, A33 vaccination did not induce CTL
activity to the 9 mer Y104 to L112 predicted epitope of
A33VACV (Table 1). Surprisingly the L112F substituted
epitope (found in A33CPXV) induced a low level of CTL
activity, yet it did not correlate with in-vivo protection.
Since L112F substitution retained the protective ability
of A33 we conclude that at least in the BALB/c mouse
model, this epitope does not induce T-cell dependent
cytotoxicity. As L112F substitution is also found in
A33VARV, we tested the possibility that this substitution
may render VARV resistant to A33-based vaccination. In
humans, two overlapping predicted A33VACV CTL epi-
topes were mapped at this region spanning aa 102–111rbidity (B) in mice vaccinated with various A33 constructs. BALB/c mice
33 proteins or with a control Sindbis pTE as indicated. 14 days later
esponding to 20 LD50). (n = 5 per group). Error bars represent standard
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[38] and 109–118 (NetCTL prediction, CBS). Despite
strong in-vitro binding of the former epitope (aa 102–
111) to A0201 allele, CTL activity (IFNγ release) was
not detected [39]. Additionally, the L112F variation
found in A33VARV is not predicted to affect the anchor-
ing to the A0201 molecule. Thus, our experimental data
and previous studies do not support the presence of a
functional CTL epitope within the CP-II region,
suggesting that F112 substitution found in A33VARV
most probably will not abrogate protective immunity
through vaccination with A33VACV.
We evaluated several single aa substitutions in the CP-
II region and demonstrated that L118 is the only residue
which is crucial for protection against VACV-WR. These
results are in complete agreement with the mapping of
the binding epitope of the protective/neutralizing mono-
clonal antibody MAb-1G10 [26]. In that study, the
L118S change in MPXV was shown to be detrimental
for the MAb-1G10 binding and the Q117K substitution
partially restored this binding [26]. In our hands, sera
from mice vaccinated with an A33 harboring the L118S
substitution exhibited a lower antibody titer reflected by
reduced comet inhibition potency. It was previously
demonstrated that comet inhibition activity correlates
with protection against lethal VACV-WR challenge [40].
It appears that the inability of A33 to protect BALB/c
mice against CPXV challenge, most likely results from the
inability of the A33VACV-induced protective antibodies to
recognize A33CPXV. It is possible that the L118S substitu-
tion, replacing a non-polar hydrophobic with a polar-
hydrophilic residue, interferes with antibody binding to
the epitope containing L118.
We showed that vaccination with A33CPXV did not pro-
tect against CPXV challenge and only partially protected
against VACV-WR challenge (Figure 4). These results sup-
port the study mentioned above, using the MPXV
ortholog of A33 (A33MPXV) which also partially protected
against VACV-WR challenge [26]. Unlike CPXV, both
MPXV and ECTV encode the E120 residue that is be-
lieved to compensate for the L118S substitution found in
A33MPXV and A33ECTV (Figure 6A). In this work we fur-
ther show the critical role of L118 in protection against le-
thal challenge with VACV-WR by active vaccination.
Having the same mouse model for VACV-WR, CPXV and
ECTV, allowed us to evaluate the differential cross-
protection capacity of A33, and allowed to demonstrate
the critical role of L118 and the compensatory role of
Q117 and E120.
The results also agree with previous work by He et al.
[27], substantiating the essential role of L118 in binding
of protective antibodies to A33. In that work, an import-
ant role in antibody binding to the epitope is attributed
to the D115 residue, yet D115 is conserved betweenVACV and CPXV excluding its contribution to the
mechanism utilized by CPXV to evade A33 immunity.
Our work shows that active vaccination with A33 in-
duces immunity to a single protective epitope and sug-
gests that the mechanism of protection involves
induction of MAb-1G10 like neutralizing antibodies.
This epitope overlaps an immunogenic region in A33,
previously mapped in primates to mount antibody re-
sponse [5,24,41], further emphasizing the importance of
this region for future vaccines.
We show that the L118S substitution abrogated pro-
tection, which was partially restored, by the double mu-
tant Q117K-L118S. This correlates with partial restoration
of the binding of MAb-1G10 antibodies to A33 by the
Q117K substitution [26]. This suggests that beside the
major L118 residue, other residues, within the protective
epitope, contribute to protection. Indeed, A33VACV pro-
tects BALB/c against ECTV challenge. A33ECTV bares the
same Q117K-L118S substitutions, and similarly to MPXV
has an additional S120E substitution, not found in CPXV.
This substitution was shown to improve binding of the
MAb-1G10 neutralizing antibody [26], pointing toward
E120 as a compensatory residue. It is possible that
boosting immunization with A33 enhances an immune re-
sponse through additional weak epitopes that support pro-
tection in very low challenge doses of CPXV [42].
Having demonstrated that replacement of CP-II elimi-
nates the protection afforded by A33 and that CP-I re-
placement was as protective as A33VACV it was reasonable
to suggest that a major protective epitope is located within
CP-II, as demonstrated in the manuscript. Whether CP-I
replacement synergize with CP-II cannot be simply tested
because CP-II of CPXV was already associated with 100%
lethality. Nevertheless, based on the partial protection
against VACV-WR afforded by vaccination with A33CPXV
we cannot exclude the possibility that the CP-I region har-
bors a compensatory function to the CP-II region. This
possibility was not tested.
CPXV utilizes several mechanisms of immune evasion
including inhibition of TAP dependent antigen process-
ing, inhibition of MHC class I peptide loading, inhibition
of cell surface presentation of MHC class I molecules
and expression of large set of immune modulating genes
[43]. Whether modifying a few residues within a major
protective epitope prevents the binding of neutralizing
antibodies to A33 thus allowing CPXV to evade A33 im-
munity, remains to be demonstrated.
The immune protection conferred by VACV and its an-
tigens, against VARV and other orthopoxviruses is based
on cross-protection. This fact, and the development of
subunit vaccines and monoclonal antibody-based thera-
peutic products, strongly suggest that sequence variation
between the species should be carefully assessed. Mapping
the basis for the protective ability of A33 at the single
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lights this aspect of cross-reactivity and sequence variation
that affect protection.
Materials and methods
Viruses, cells and antibodies
Vero (ATCC-CCL-8), BHK 21 (ATCC-CCL-10) RK-13
(ATCC-CCL-37) and BS-C-1 (ATCC-CCL-26) cells were
maintained as recommended by ATCC. Vaccinia Lister
(Israel Ministry of Health), VACV-WR (ATCC VR-119),
CPXV strain Brighton-red (ATCC VR-302) and IHD-J
were propagated and tittered as described previously [28].
Sindbis virus (pTE32J) was prepared as described [25].
Briefly, capped pTE32J RNA was generated by in-vitro
transcription using SP6 RNA polymerase and transfected
to BHK-21 cells using Lipofectin (invitrogen) according to
the manufacturer protocol. Viruses were collected from
the culture medium 48 hours post transfection, reinfected
to BHK-21 cells and the viruses were collected from the
culture medium, concentrated by the slow addition of
Polyethylene-glycol (PEG) 8,000 and NaCl (Sigma) to
reach a 40% PEG 2 N NaCl concentration. Following
60 minutes incubation at 4°C, viruses were pelleted at
11,000 g for 60 minutes at 4°C, and the pellet was
resuspended in PBS. The concentrated viruses were ti-
trated on BHK cells and maintained in aliquots at −80°C.
A33 antisera was generated as described [44]. Mouse anti
β Tubulin antibody was purchased from Sigma. Mouse
and rabbit anti Sindbis antisera were generated by re-
peated vaccination of mice and rabbits with Sindbis virus.
Rabbit anti A33 was obtained by repeated vaccination with
bacterially expressed, affinity purified, His-tagged A33.
DNA sequences and CTL predictions
The following sequences were used for DNA sequence
alignments: VACV-WR (Vaccinia virus WR, accession#
NC006998), CPXV-BR (Cowpox virus Brighton-red,
NC003663), VACV-Lister (AY678276), ECTV-Moscow
(Ectromelia virus Moscow, NC004105), MPXV-ZAR
(Monkeypox virus Zair, NC003310) and VARV-BGD74_
sol (Variola virus Bangladesh 1974, DQ441422). Predic-
tion of CTL epitopes were performed using NetMHC
(http://www.cbs.dtu.dk/services/NetMHC), SYFPEITHI
(http://www.syfpeithi.de/bin/MHCServer.dll/EpitopePre
diction.htm), and BIMAS (http://www-bimas.cit.nih.
gov/molbio/hla_bind).
Cloning and expression of A33
A33R gene from VACV Lister or CPXV Brighton-red
DNA was amplified and cloned to the pH3 shuttle vector
and transferred to the pTE3 vector [25]. Point mutations
and domain swapping were generated by PCR, and vali-
dated by DNA sequencing. Expression of A33 in BHK-21
infected cells was determined by immunofluorescencemicroscopy and western blotting as previously described
[45] using rabbit anti-A33 antibody, mouse anti-Sindbis
antibody and anti β-Tubulin (Sigma) antibody. HRP,
Alexa-fluor 488 and Alexa-fluor 555 conjugated anti-
rabbit and anti-mouse conjugated antibodies (Molecular
probes) were used according to the manufacturer’s proto-
cols. DAPI (Sigma) was used according to the manufac-
turer’s protocols to stain nuclear DNA. Immunofluorescent
microscopy was performed using an axiovert Zeiss micro-
scope. Image acquisition was performed, maintaining the
same settings for all samples, using a DS-Ri1 CCD (Nikon).
Bacterially expressed, His-tagged A33, was used for
rabbits immunization. To achieve that goal, A33VACV
from VACV Lister was cloned into pRSET plasmid
(invitrogen) and expressed in BL21::pLysS bacteria.
A33 was purified from the cell lysates on a Nickel-
agarose (NiNTA) column (Qiagen) according to the
manufacturer’s protocol, analyzed on SDS-PAGE and
formulated for vaccination with complete or incom-
plete Freund adjuvant (Sigma) according to the manu-
facturer protocols.Enzyme linked immunosorbent assay (ELISA)
Antibody titer to Vaccinia virus was determined by
ELISA as described [28]. Briefly, microtiter plates were
coated with 50 ng purified bacterially expressed 6xHis
tagged A33VACV. The protein was purified from whole
8 M Urea denatured bacterial lysates on a NiNTA resin
(Qiagen) and dialyzed against PBS. Following adsorption,
plates were blocked, incubated with two-fold serial
serum dilutions and then subsequently with alkaline
phosphatase conjugated goat anti mouse IgG (1:1000,
Sigma-Aldrich). GMT and GeoSTDEV were calculated
as described [28].Comet inhibition assay
Comet inhibition assay in mouse sera was determined as
described previously [23]. Briefly, fresh preparation of
IHD-J, diluted in Earle’s modified Eagle medium, sup-
plemented with 2% heat-inactivated fetal bovine serum
to give approximately 50 plaques was used to infect
monolayers of BS-C-1 cells. After 2 h at 37°C, the inocu-
lum was removed and the cells were washed. A liquid
overlay, consisting of Earle’s modified Eagle medium,
supplemented with 2% heat-inactivated fetal bovine
serum and serial dilutions of sera obtained from the A33
vaccinated mice as indicated. After 48 h, the medium
was aspirated and the cells were stained – fixed with
0.1% (W/V) crystal-violet (Merk) in 20% ethanol. The
stain was aspirated and the wells were washed with tap-
water and dried. Comet inhibition capacity is determined
by the minimal serum dilution exhibiting such activity.
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BALB/c and CD-1 female mice (5–7 weeks old, Charles
Rivers, UK) were vaccinated by intraperitoneal injection
(i.p) with 1×107pfu of the various Sindbis viruses diluted
in phosphate buffered saline (PBS). Intranasal challenge
with VACV-WR or CPXV was performed as previously
described [28]. To induce pocks on the tails, CD-1 mice
were similarly vaccinated with the various Sindbis viruses
or with 1×106pfu of VACV-Lister by tail scarification and
14 days later were intravenously injected with 1×104pfu of
VACV-WR. 8 days later the tails were stained with 0.1%
Trypan blue and pocks were counted. The method of tail
scarification as well as the calculation of the lethal dose of
50% for BALB/c mice (LD50) were performed as described
[28]. The end-points were weight loss of 40% of the initial
weight and/or the inability to respond to the righting
reflex. Animals that reached these predetermined end-
points were humanely sacrificed. LD50 values by i.n. in-
stillation in BALB/c mice were determined as: 2×104pfu
for VACV-WR, 1×105pfu for CPXV and 1 pfu for
ECTV. LD50 of ECTV by i.f.p. injection was 10 pfu. In-
jection i.v. of 1×104pfu VACV-WR to CD-1 mice was
not lethal. Animal experiments were repeated at least
twice and conducted in compliance with the regulations
for animal experiments of the IACUC at the Israel Insti-
tute for Biological Research.In-vivo cytotoxicity assay
MHC class I–dependent cytotoxicity assay was modified
from [46]. In brief, syngeneic splenocytes were harvested
from naïve BALB/c mice and labeled with either DiI or
DiD (invitrogen) according to the manufacturer manual.
DiI labeled cells were pulsed with a vaccinia CD8+ T-cell
epitope with the amino acids sequence KYGRLFNEI
(corresponding to -A52VACV75-83) [47] or with the puta-
tive Kd T-cell epitope from A33CPXV104-112 (YYQGSCYIF)
or with the putative Kd T-cell epitope from A33VACV104-112
(YYQGSCYIL) at a final concentration of 1 μg/ml. DiD la-
beled cells were pulsed with a T-cell epitope of influenza-
A/H3N2/Texas/1/77 NP147-158 (TYQRTRALVRTG) [37]
as control at a final concentration of 1 μg/ml. A52VACV5-83
and influenza-A/H3N2/Texas/1/77 NP147-158 are restricted
to Kd. DiI and DiD labeled cells were mixed to 1:1 ratio
and 2×107 cells were injected into the tail vain of naïve or
vaccinated BALB/c mice. 4 hours after injection recipient
animals were sacrificed and their spleens were removed.
The amount of DiI and DiD labeled cells from the spleens
was determined by flow cytometry (FACScalibur, BD) and
analyzed with the Flowjo software (Tree Star). Specific lysis
was calculated with the following formula:
%specific lysis ¼ 1− ratio unvaccinated
ratio vaccinated
 
 100Where ratio ¼ %DiD labelled cells
%Dil labelled cells
Statistical analysis
The area under the curve (AUC) to compare morbidity
based on weight loss was calculated for each mouse and
mean AUC’s of various groups were compared using
two-sample Student t-test (GraphPad Prism, Irvine, CA).
Significance between antibody titers was calculated using
two-tailed, unpaired Student t-test (GraphPad Prism,
Irvine, CA).
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